Cramer's Morning Take: Bristol Myers 12/16/24

Discover the excitement behind Bristol-Myers' stock surge thanks to promising drug developments like Cobenphie for schizophrenia. The discussion highlights impressive sales projections and the company's attractive dividend yield. A disciplined approach to investments is emphasized, encouraging selective decision-making amid market dips. Join the conversation about navigating the challenges of the current market landscape while seizing potential opportunities.